GENINUS Inc. (KOSDAQ: A389030)
Health Care · Biotechnology · KR
₩2,055.00
+0.98% today · +30.7% 1Y
GENINUS Inc. (KOSDAQ: A389030) operates in the Biotechnology industry within the Health Care sector. The company is valued at $58.47M.
Over the last twelve months the share price has gained 30.7%, trading between 1.49K and 6.48K.
Tweenvest scores GENINUS Inc. across four factors: quality 27/100, value 60/100. Its strongest factor is value.
A389030 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $58.47M
- Revenue (TTM)
- $6.73M
- P/E
- —
- EPS
- -510.40
- Dividend yield
- —
- Beta (5Y)
- 0.15
- 52-week high
- ₩6,480.00
- 52-week low
- ₩1,490.00
- Avg volume (3M)
- —
- Shares outstanding
- 39.39M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.